Bulletin
Investor Alert

New York Markets Open in:

VBI Vaccines Inc.

NAS: VBIV

GO
/marketstate/country/us

Before the Bell

 --Real time quotes

Jan 22, 2021, 8:00 a.m.

/zigman2/quotes/201705917/composite

$

3.07

Change

-0.01 -0.33%

Volume

Volume 18,711

Real time quotes

/zigman2/quotes/201705917/composite

Previous close

$ 3.08

$ 3.08

Change

-0.22 -6.53%

Day low

Day high

$3.06

$3.52

Open

52 week low

52 week high

$0.69

$6.93

Open

Company Description

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like ...

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

74.22

Price to Book Ratio

2.79

Enterprise Value to Sales

61.65

Total Debt to Enterprise Value

0.12

Efficiency

Revenue/Employee

17,768.00

Income Per Employee

-438,504.00

Receivables Turnover

17.28

Total Asset Turnover

0.02

Liquidity

Current Ratio

1.57

Quick Ratio

1.54

Cash Ratio

1.49

Profitability

Gross Margin

-310.09

Operating Margin

-2,075.96

Pretax Margin

-2,467.94

Net Margin

-2,467.94

Return on Assets

-42.20

Return on Equity

-58.82

Return on Total Capital

-42.55

Return on Invested Capital

-54.78

Capital Structure

Total Debt to Total Equity

18.47

Total Debt to Total Capital

15.59

Total Debt to Total Assets

13.34

Long-Term Debt to Equity

0.93

Long-Term Debt to Total Capital

0.78

Officers and Executives

Name Age Officer Since Title
Mr. Jeffrey R. Baxter 57 2016 President, Chief Executive Officer & Director
Mr. Christopher McNulty 42 2018 CFO & Head-Business Development
Dr. David Evander Anderson 49 2016 Chief Scientific Officer
Dr. Francisco Diaz-Mitoma 64 2016 Chief Medical Officer
Ms. Nell Beattie 31 2015 Director-Corporate Development & IR

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/24/2020 Perceptive Advisors LLC
9,090,909   Acquisition at $1.1 per share. 9,999,999
10/04/2019 Francisco Diaz-Mitoma
Chief Medical Officer
40,000   Acquisition at $0.5 per share. 20,000
09/30/2019 Jeffrey R. Baxter
CEO, President; Director
150,000   Acquisition at $0.5 per share. 75,000
09/30/2019 Francisco Diaz-Mitoma
Chief Medical Officer
14,500   Acquisition at $0.5 per share. 7,250
09/23/2019 Perceptive Advisors LLC
20,000,000   Acquisition at $0.5 per share. 10,000,000
06/27/2019 Francisco Diaz-Mitoma
Chief Medical Officer
8,000   Acquisition at $1.07 per share. 8,560
06/20/2019 Francisco Diaz-Mitoma
Chief Medical Officer
42,000   Acquisition at $0.89 per share. 37,380
06/20/2019 Francisco Diaz-Mitoma
Chief Medical Officer
10,000   Acquisition at $0.78 per share. 7,800
06/19/2019 Jeffrey R. Baxter
CEO, President; Director
144,000   Acquisition at $0.73 per share. 105,120
06/19/2019 Nell Beattie
Chief Business Officer
8,000   Acquisition at $0.74 per share. 5,920
06/17/2019 Perceptive Advisors LLC
1,000,000   Acquisition at $0.62 per share. 620,000
06/14/2019 Jeffrey R. Baxter
CEO, President; Director
31,250   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 David Evander Anderson
Chief Scientific Officer
21,875   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 Steven H. Gillis
Director
18,750   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 Nell Beattie
Chief Business Officer
6,250   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 Michel de Wilde
Director
12,500   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2019 David Evander Anderson
Chief Scientific Officer
25,000   Award at $0 per share. 0
01/31/2019 Avi Mazaltov
Head Global MFG&GM-SciVac Ltd.
90,000   Award at $0 per share. 0
01/31/2019 Nell Beattie
Chief Business Officer
15,000   Award at $0 per share. 0
01/31/2019 Christopher McNulty
CFO and Head of BD
25,000   Award at $0 per share. 0
/news/latest/company/us/vbiv

MarketWatch News on VBIV

  1. A Biotech Pro Bought Up These 3 Stocks

    6:00 a.m. Sept. 19, 2020

    - Barron's Online

  2. VBI Vaccines upgraded to strong buy from outperform at Raymond James, price target raised $1 to $9

    8:12 a.m. Aug. 27, 2020

    - Tonya Garcia

  3. VBI Vaccines stock price target raised to $5 from $4 at BMO Capital

    9:06 a.m. Jan. 10, 2020

    - Tomi Kilgore

  4. VBI Vaccines started at outperform with $3 stock price target at Raymond James

    7:52 a.m. Nov. 14, 2019

    - Tomi Kilgore

  5. Tegna, First United, Alico, and Other 13D Filings

    8:30 p.m. Oct. 4, 2019

    - Barron's Online

  6. Vintage Capital Takes Bite from Red Robin

    9:39 p.m. June 28, 2019

    - Barron's Online

  7. A Biotech Pro Loaded Up on These 2 Stocks

    6:30 a.m. June 23, 2019

    - Barron's Online

  8. 5 things to know about Hookipa Pharma ahead of its IPO

    6:26 a.m. April 18, 2019

    - Sarah Toy

  9. VBI Vaccines started at outperform with $9 stock price target at Oppenheimer

    9:15 a.m. Jan. 16, 2019

    - Tomi Kilgore

  10. VBI Vaccines started at outperform with $11 stock price target at BMO Capital

    9:35 a.m. Nov. 15, 2017

    - Tomi Kilgore

  11. Viex Sees Potential in Babcock & Wilcox

    10:12 p.m. Nov. 3, 2017

    - Barron's Online

  12. VBI Vaccines started at buy with $7 stock price target at Ladenburg Thalmann

    8:05 a.m. July 26, 2016

    - Tomi Kilgore

  13. A year after Lehman collapse, few execs resurface

    2:40 a.m. Sept. 8, 2009

    - Alistair Barr

  14. Doctor, Heal Thyself

    12:01 a.m. Nov. 27, 2006

    - Barron's Online

  15. Paulson Capital declares special 15c cash div

    3:24 p.m. Jan. 27, 2005

    - Heather Wilson

  16. Paulson Capital declares special 15c div

    3:21 p.m. Jan. 27, 2005

    - Heather Wilson

  17. Paulson Capital div record date on Feb. 10

    3:21 p.m. Jan. 27, 2005

    - Heather Wilson

  18. Paulson Capital Q3 rev $4.7M vs $12M

    2:34 p.m. Aug. 12, 2004

    - Heather Wilson

  19. Paulson Capital Q2 net loss 8c vs $1.91

    2:32 p.m. Aug. 12, 2004

    - Heather Wilson

  20. Paulson Capital Q1 net loss 11c vs $1.73

    12:24 p.m. May 13, 2004

    - Carla Mozee

  21. Loading more headlines...
/news/nonmarketwatch/company/us/vbiv

Other News on VBIV

  1. Why is U.S. vaccine rollout taking longer than expected?

    4:20 a.m. Today

    - Seeking Alpha

  2. VBI Vaccines updates on the COVID-19 study progress

    10:52 a.m. Jan. 21, 2021

    - Seeking Alpha

  3. ACB, APHA among premarket gainers

    8:29 a.m. Jan. 15, 2021

    - Seeking Alpha

  4. The world will have to live with COVID forever - Moderna CEO

    4:38 a.m. Jan. 14, 2021

    - Seeking Alpha

  5. VBI Vaccines: Time To Meet Guidance

    12:52 a.m. Jan. 13, 2021

    - Seeking Alpha

  6. 8 Penny Stocks to Avoid in 2021

    3:24 p.m. Jan. 11, 2021

    - InvestorPlace.com

  7. Could a COVID vaccine passport be issued in the U.S.?

    9:38 a.m. Jan. 3, 2021

    - Seeking Alpha

  8. Israel leads world in COVID vaccinations per capita

    8:07 a.m. Jan. 1, 2021

    - Seeking Alpha

  9. VBI Vaccines’ Hep B vaccine goes under review in EU

    8:46 a.m. Dec. 23, 2020

    - Seeking Alpha

  10. Will vaccines work against the U.K. coronavirus variant?

    5:00 a.m. Dec. 22, 2020

    - Seeking Alpha

  11. VBI Vaccines files US application for HBV vaccine

    9:39 a.m. Dec. 1, 2020

    - Seeking Alpha

  12. Vaccine access and distribution a big topic at G20

    9:12 a.m. Nov. 22, 2020

    - Seeking Alpha

  13. VBI Vaccines' (VBIV) Early Data on HBV Candidate Positive

    10:45 a.m. Nov. 19, 2020

    - Zacks.com

  14. Loading more headlines...

At a Glance

VBI Vaccines, Inc.

222 3rd Street

Suite 2241

Cambridge, Massachusetts 02142

Phone

1 6178303031

Industry

-

Sector

-

Fiscal Year-end

12/2020

Revenue

$2.22M

Net Income

$-54.81M

Employees

125.00

/news/pressrelease/company/us/vbiv

Press Releases on VBIV

  1. VBI Vaccines Announces Progress of Coronavirus Vaccine Program

    8:00 a.m. Jan. 21, 2021

    - BusinessWire - BZX

  2. Monday's ETF Movers: XBI, OIH

    12:05 p.m. Nov. 30, 2020

    - MarketNewsVideo.com

  3. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.